Audiogene, the first clinical trial in France for a gene therapy to treat hearing loss in children

The aim of this clinical trial, which has just received approval in France, is to assess the safety and efficacy of a new gene therapy drug in children aged between 6 and 31 months with profound hearing loss. Audiogene was developed by a French consortium composed of teams from the Hearing Institute, an Institut Pasteur research center; the ENT Department and Pediatric Audiology Research Center at Necker-Enfants Malades Hospital (AP-HP); Sensorion and the Fondation Pour l'Audition. The trial has also been submitted to other European countries and is currently undergoing assessment.

Find out more (in French)